Publications by authors named "D G Aynekulu Mersha"
Article Synopsis
- The PreLeisH study investigated Leishmania markers in HIV-positive individuals at risk of visceral leishmaniasis (VL) in Ethiopia, aiming to predict VL and create a management strategy.
- Over two years, researchers tracked 490 participants, finding that specific Leishmania tests could effectively indicate VL risk levels, with 92.3% classified as low risk.
- The study highlights the importance of identifying high-risk individuals for targeted intervention, emphasizing the need for further research in this area.
Article Synopsis
- There is a problem with both HIV and visceral leishmaniasis (VL) infections in Ethiopia, making it hard to treat VL in people who also have HIV.
- Researchers found that certain genes (HLA) can help predict who might get sick from VL, especially in people with HIV.
- In a study of people living in Ethiopia, they found a specific gene (HLA-A*03:01) that is linked to a higher risk of developing VL, which could help improve treatment strategies in the future.
The textile industry uses a lot of adhesives to join materials together, and many of these adhesives use petroleum-based ingredients that are harmful to the environment. To replace petroleum-based adhesives with a more environmentally friendly option for the textile industry, this study set out to create and evaluate a hot-melt adhesive derived from cassava starch. By adding kaolin clay as a filler and tannin as a tackifier in different ratios of starch, the created adhesive was enhanced.
View Article and Find Full Text PDFA large proportion of HIV-coinfected visceral leishmaniasis (VL-HIV) patients exhibit chronic disease with frequent VL recurrence. However, knowledge on immunological determinants underlying the disease course is scarce. We longitudinally profiled the circulatory cellular immunity of an Ethiopian HIV cohort that included VL developers.
View Article and Find Full Text PDFBackground: This study aimed to determine whether paromomycin plus miltefosine (PM/MF) is noninferior to sodium stibogluconate plus paromomycin (SSG/PM) for treatment of primary visceral leishmaniasis in eastern Africa.
Methods: An open-label, phase 3, randomized, controlled trial was conducted in adult and pediatric patients at 7 sites in eastern Africa. Patients were randomly assigned to either 20 mg/kg paromomycin plus allometric dose of miltefosine (14 days), or 20 mg/kg sodium stibogluconate plus 15 mg/kg paromomycin (17 days).